The 4S 7 , CARE 8 and LIPID 9 trials clearly showed the benefits of statins in patients with diagnosed coronary disease and with average and above-average cholesterol levels. The Heart Protection Study (HPS) set out to assess the effect of statin therapy in cardiac patients with belowaverage cholesterol levels and also other high-risk groups such as those patients with non-coronary occlusive arterial disease such as PAD. 12
Intermittent claudication affects between 1.7% 1 and 7.1% 2 of the population over 55 years of age. In terms of the limb, the condition is relatively benign, with fewer than 10% of claudicants requiring intervention to prevent limb loss and fewer than 1% per year requiring amputation. 3 However, patients with intermittent claudication have a two to four times increased mortality from cardiovascular causes and are at as great a risk of dying from a heart attack as many patients who have survived their first myocardial infarction. 4 Epidemiological, post mortem and angiographic studies have consistently shown a strong positive correlation between plasma total cholesterol and the incidence of coronary heart disease (CHD). 5 In Western populations, the increased risk of future cardiovascular events is observed with serum cholesterol levels that were considered to be in the normal range and increases progressively in a linear manner with rising cholesterol concentrations. 5 This socalled normal range merely represents a national average as other nations have much lower serum cholesterol concentrations and correspondingly a reduced incidence of cardiac disease. However, even in populations with low serum cholesterol levels, such as Japan, an independent graded association between cholesterol levels and cardiac events has been shown to exist. 6 Although there may be debate regarding the threshold for cholesterol, reducing the high serum cholesterol concentrations seen in Western populations has been shown to reduce adverse cardiovascular outcomes. 7À9
Evidence for lipid-lowering therapy: HMG-coA reductase inhibitors (statins)
CHD
The three large secondary prevention trials in patients with CHD À the Scandinavian Simvastatin Survival Study (4S), 7 the Cholesterol And Recurrent Events trial (CARE) 8 and the Long-term Intervention with Pravastatin in Ischaemic Disease study (LIPID) 9 À have demonstrated conclusively that effective lipid-lowering therapy reduces coronary events. These trials totalled over 17 000 patients and provided level I evidence of a significant reduction of the order of 25% in non-fatal myocardial infarction and coronary death total in patients with a history of CHD treated with statins. The remainder of this review will specifically address the evidence for the use of statins in patients with peripheral arterial disease (PAD).
PAD
The LIPID study included among 9014 patients aged 31À75 years with prior acute myocardial infarction or unstable angina, 995 patients with claudication at baseline. 10 During the 6-year follow-up, 38% of patients with claudication at baseline and 27.5% of those without claudication had a CHD event, stroke, peripheral vascular event or associated surgery. The patients with claudication had a higher risk of cardiovascular death (13%) compared with those without claudication (8%). In patients with claudication at baseline, pravastatin 40 mg daily significantly reduced the risk of CHD events, stroke and peripheral vascular events (p ¼ 0.039) compared with placebo 10 ( Table 1 ).
Aronow and Ahn 11 assessed the effect of statin versus no lipid-lowering therapy in an observational study of 660 patients with symptomatic PAD, including critical limb ischaemia, with a mean age of 80 years (range 60À99 years). Patients on a statin had a 48% incidence of new coronary events compared to a 73% incidence in patients not on lipid-lowering therapy at a mean followup of 39 months (p < 0.001). The benefit of statins was observed in patients with and without prior myocardial infarction.
In the HPS, over 20 000 patients with a history of coronary or cerebrovascular disease, PAD or diabetes were randomized to receive 40 mg simvastatin daily or placebo for 5 years. 12 Patients were aged 40À80 years and had a baseline cholesterol level greater than 3.5 mmol=l. Primary outcomes were mortality and fatal or non-fatal vascular events with subsidiary assessments of major morbidity. The study included 6748 patients with PAD, of which 2701 had no history of coronary disease. Primary outcomes were mortality and fatal or non-fatal vascular events with subsidiary assessments of major morbidity. Compliance in the statin group was 85%, and 17% of the placebo group were found to be taking a non-study statin. Thus, the intention to treat analysis assessed the effects of about two-thirds taking a statin during the study treatment period.
Overall mortality was significantly reduced in the patients on statin therapy (12.9% versus 14.7%), due mainly to a reduction in the coronary death rate. There was a 24% reduction in the rates of myocardial infarction, of stroke or of revascularization in patients randomized to simvastatin ( Table 2 ). There was a dramatic 38% reduction in the incidence rate of first non-fatal myocardial infarction in those patients randomized to simvastatin. The average reduction in blood levels of total cholesterol was 2 mmol=l and LDL cholesterol 1.5 mmol=l.
For patients with PAD, 5 years of simvastatin therapy was estimated to prevent 70 per 1000 patients from suffering a major vascular event. 12 Thus, adding simvastatin to existing secondary prevention therapy in patients with PAD, safely and effectively reduces the risk of future cardiovascular events. The size of the benefit depended on individuals' overall cardiovascular risks and occurred irrespective of their cholesterol levels ( Table 2 ).
Statins and walking distances
In the Heart Protection Study, 12 4S, 7 CARE 8 and LIPID 9 trials, patients on statins have achieved greater risk reduction than that predicted by lipid modification alone, suggesting that these drugs have other pleotrophic effects. A full discussion of the ancillary modes of action of statins is beyond the scope of this review. However, statins have been shown to slow the progression of plaques in the femoral, carotid and coronary arteries and in early atherosclerosis have been shown to promote regression of atherosclerotic lesions. 13 This observation has lead to the theory that the anti-inflammatory and plaque stabilizing actions of statins may improve walking distances in patients with intermittent claudication.
The Scandinavian Simvastatin Survival study provided level I evidence that cardiac patients randomized to simvastatin had a 38% reduction in new or worsening claudication compared with patients randomized to placebo over a median follow-up of 5.4 years (p ¼ 0.008). 14 Further level I evidence of the effect of statins on functional activity was provided by Mohler et al via a randomized, doubleblind study of 354 patients with intermittent claudication who were randomized to placebo or to atorvastatin (10 or 80 mg). 15 The use of a statin was found to improve pain-free walking distance and community-based physical activity in patients with intermittent claudication after 12 months of treatment. However, there was no change in maximal walking distance or quality of life. Mondillo et al, in a randomized, double-blind, controlled trial of 86 patients, showed that a 6-month treatment with simvastatin significantly increased pain-free and maximal walking distances, and the ankleÀbrachial pressure index in patients with claudication. 16 
Dose=compliance
Patients should be commenced on the doses recommended in the major secondary prevention trials and should not undergo dose titration. In the HPS, 15% of people randomized to statin therapy stopped taking it throughout the 5year study. However, there was a 'run-in' period prior to the trial commencing and thus the overall non-compliance rate may be higher.
Side effects
Statins differ in their metabolism, particularly with respect to P450 cytochrome and drug interactions. 18 All statins cause rhabdomyolysis by an unknown mechanism. Cerivastatin was recently withdrawn due to a significantly higher rate of rhabdomyolysis, particularly in the elderly, at high doses, in combination with gemfibrozil. In the HPS, unexplained muscle pain or weakness occurred in 32% of patients on statin therapy and 33% on placebo. Myopathy defined as muscle symptoms and creatine kinase elevated greater than 10 times the upper limit of normal occurred in 0.11% in the statin group and 0.05% in the placebo group (p > 0.05). Rhabdomyolysis defined as a creatine kinase elevated greater than 40 times the upper limit of normal occurred in 0.05% of patients on a statin and 0.03% on placebo. It should, however, be noted that in the HPS 32 105 patients were enrolled in a pre-randomization run-in and 11 609 were not enrolled in the study. Thus, the HPS may not reflect the natural history of myalgia and myositis in the community. In all the other secondary prevention studies there was no significant increase in these complications in the treatment arm compared to placebo. In the 4 S study, in the treatment arm, the incidence of myopathy was 0.27% and there was one case of rhabdomyolysis (0.05%). 7 In the CARE study, there were no reported episodes of myositis in the treatment group but in the PROSPER study the incidence of myalgia in the pravastatin group was 1.3% and there were no reported cases of rhabdomyolysis. 17 Due to the very small but serious risk of rhabdomyolysis, patients should be asked to promptly report unexplained muscle pain, tenderness or weakness. Statins are contraindicated in patients with chronic liver disease. In the HPS, abnormalities of liver enzymes, defined as a three times increase in alanine aminotransferase, occurred in 0.8% of patients on statin treatment for 5 years or more and 0.6% of patients randomized to placebo. In the 4S and the LIPID studies, an elevated alanine amino transferase occurred in 2.2% and 2.1% of patients in the treatment arm (p > 0.05 compared with placebo). Safety data for the randomized controlled trials would therefore suggest that routine monitoring of liver function tests in patients on statins is not necessary. No differences in the incidence of cancers or respiratory disease were noted in the HPS.
Evidence for lipid-lowering therapy in PAD: fibrates
The effect of bezafibrate on the risk of CHD and stroke in men with lower extremity arterial disease has been assessed in a double-blind, randomized, placebo-controlled trial of 1568 men aged 35À92. 19 Bezafibrate did not reduce the incidence of CHD or stroke combined. However, it appeared to have some benefit in reducing non-fatal coronary events in patients aged less than 65 years on entry into the trial and bezafibrate did reduce the severity of intermittent claudication as assessed by the Edinburgh Claudication questionnaire for up to 3 years but not in years 4 and 5 of follow-up.
Evidence for lipid-lowering therapy in PAD: probucol, bile acid sequesters, nicotinic acid and dietary modification A Cochrane review published in 2000, before the publication of the HPS and bezafibrate trial, addressed the effect of non-statin or fibrate lipid-lowering therapy in patients with PAD. 20 Seven randomized trials involving 698 patients were identified, using a variety of drugsÀ probucol, bile acid sequesters, nicotinic acid, marine triglycerides À with or without dietary modification. The analysis showed a marked but non-specific reduction in mortality but little change in non-fatal events. These lipid-lowering drugs have now been superseded by the statins. There is also no role for low-fat diets alone in the treatment of dyslipidaemia as the maximum reduction in serum cholesterol and LDL-cholesterol is less than 10% and long-term compliance is low. 21
Dyslipidaemia: national guidelines
The US National Cholesterol Education Project (Adult Treatment Panel III) (NCEP ATP III) guidelines (2001) and the joint British recommendations on the prevention of CHD in clinical practice (1998) state that patients with PAD should be managed in the same way as those with established CHD. 4, 22 Lipid-lowering therapy should aim to reduce the serum cholesterol to an optimum level of less than 200 mg=dl and low density lipoprotein (LDL) cholesterol to less than 100 mg=dl in order to meet the US guidelines. The UK guidelines aim to reduce total cholesterol to less than 5 mmol=l (192mg=dl) or by 25% and LDL cholesterol to less than 3.00mmol=l (116mg=dl) or by 30%, whichever is greater These guidelines were based on the findings of three large, major, randomized controlled, secondary prevention trials involving pravastatin and simvastatin À 4S, 7 CARE 8 and LIPID. 9 Evidence suggests that in the US and Britain, despite national guidelines recommending aggressive lowering of cholesterol in all patients with overt atherosclerosis, patients with PAD are less intensively treated compared with those with CHD. 23 A survey of members of the Vascular Surgical Society of Great Britain & Ireland performed in June 2002, just prior to the publication of the HPS, revealed that 34% of consultant vascular surgeons would only treat claudicants if the total cholesterol was greater than 5.5 mmol=l (212 mg=dl). A similar survey of general practitioners found that 18% considered cholesterol lowering therapy in a claudicant to be primary and not secondary prevention and 41% would only treat levels above 5.5 mmol=l (212mg=dl). 24 Thus, there may have been a conceptual problem with applying national cardiac guidelines derived from studies involving cardiac patients to what are perceived to be non-cardiac patients. However, data are now available for the use of stains in patients with PAD and, indeed, given the result of the HPS, the current guidelines are insufficient. Incorporation of the level I evidence provided by this study would mean that all patients with PVD, as well as those with CHD, stroke or transient ischaemic attack (TIA), should be prescribed a statin irrespective of their cholesterol level provided it is greater than 3.5 mmol=l (135 mg=dl).
Recommendations: lipid-lowering therapy in patients with PAD
. There is level I evidence that statin therapy safely prevents future cardiovascular events in patients with PAD. . We recommend that all patients with a cholesterol level greater than 3.5 mmol=l (135 mg=dl) should be commenced on a statin.
